Impact of comorbidities on TNF inhibitor persistence in rheumatoid arthritis patients: An analysis of Korean National Health Insurance claims data

Rheumatology International

Volumn 32, Issue 12, 2012, Pages 3851-3856

  Cho, Soo Kyung ^a   Sung, Yoon Kyoung ^a   Choi, Chan Bum ^a   Bae, Sang Cheol ^a  

^a Hanyang University Hospital for Rheumatic Diseases   (South Korea)

Author keywords

Comorbidity; Medication persistence; Rheumatoid arthritis; TNF inhibitor

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB;

ADULT; ARTICLE; CHARLSON COMORBIDITY INDEX; CHRONIC LUNG DISEASE; COMORBIDITY; DEPRESSION; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEALTH INSURANCE; HUMAN; INTERNIST; KOREA; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; PRESCRIPTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SURVIVAL; TERTIARY HEALTH CARE; TREATMENT DURATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ASIAN CONTINENTAL ANCESTRY GROUP; DATABASES, FACTUAL; DEPRESSION; FEMALE; HUMANS; IMMUNOGLOBULIN G; KAPLAN-MEIER ESTIMATE; LIVER DISEASES; LUNG DISEASES; MALE; MIDDLE AGED; OSTEOARTHRITIS; PEPTIC ULCER; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84872272466     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-011-2312-1     Document Type: Article

References (20)

1. Kievit W, Fransen J, Adang EM et al (2011) Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: Results from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatol (Oxf) 50:196-203
2. Lipsky PE, van der Heijde DM, St Clair EW et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343:1594-1602
3. Moreland LW, SchiV MH, Baumgartner SW et al (1999) Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130:478-486
4. Weinblatt ME, Keystone EC, Furst DE et al (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 48:35-45
5. Flendrie M, Creemers MCW, Welsing PMJ, den Broeder AA, van Riel PLCM (2003) Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis Ann Rheum Dis 62(Suppl II):ii30-ii33
6. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE (2002) Predictors of infection in rheumatoid arthritis. Arthritis Rheum 46:2294-2300
7. Sikka R, Xia F, Aubert RE (2005) Estimating medication persistence using administrative claims data. Am J Manag Care 11:449-457
8. Tang B, Rahman M, Waters HC, Callegari P (2008) Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. Clin Ther 30:1375-1384
9. National Health Insurance Corporation. National Health Insurance Statistics: The Wrst half of 2008. [Cited 2009Mar 2]. Available from: Http://www.nhic.or.kr
10. Quan H, Sundararajan V, Halfon P et al (2005) Coding algorithms for deWning comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43:1130-1139
11. Carmona L, Gomez-Reino JJ (2006) Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther 8:R72
12. Saad AA, Ashcroft DM, Watson KD, Hyrich KL, Noyce PR, Deborah PM (2009) Symmons for the British Society for Rheumatology Biologics Register. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: Observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther 11:R52
13. Duclos M, Gossec L, Ruyssen-Witrand A et al (2006) Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients. J Rheumatol 33:2433-2438
14. Gabriel SE, Michaud K (2009) Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 11:229
15. Wolfe F, Michaud K (2008) The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: A cohort and nested case-control analysis. Arthritis Rheum 58:2612-2621
16. Gomez-Reino JJ, Carmona L (2006) Switching TNF antagonists in patients with chronic arthritis: An observational study of 488 patients over a four-year period. Arthritis Res Ther 8:R29
17. Kristensen LE, Gulfe A, Saxne T, Geborek P (2008) EYcacy and tolerability of anti-tumor necrosis factor therapy in psoriatic arthritis patients: Results from the South Swedish Arthritis Treatment Group. Ann Rheum Dis 67:364-369
18. Soliman MM, Ashcroft DM, Watson KD, Lunt M, Symmons DP, Hyrich KL, on behalf of the British Society for Rheumatology Biologics Register (2011) Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: Results from the British Society for Rheumatology. Biologics Register. Ann Rheum Dis 70: 583-589
19. Heiberg MS, Koldingsnes W, Mikkelsen K et al (2008) The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: Results from a longitudinal, observational, multicenter study. Arthritis Rheum 59:234-240
20. Dezii CM (2001) Persistence with drug therapy: A practical approach using administrative claims data. Manag care 10:42-45